BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21883838)

  • 21. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P; Holmäng S
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
    Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H
    Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
    Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
    J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
    Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S
    BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
    J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
    Tilki D; Reich O; Svatek RS; Karakiewicz PI; Kassouf W; Novara G; Ficarra V; Chade DC; Fritsche HM; Gerwens N; Izawa JI; Lerner SP; Schoenberg M; Stief CG; Skinner E; Lotan Y; Sagalowsky AI; Shariat SF
    J Urol; 2010 May; 183(5):1757-63. PubMed ID: 20299059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.
    Mitra AP; Skinner EC; Miranda G; Daneshmand S
    BJU Int; 2013 Feb; 111(2):240-8. PubMed ID: 22928881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy.
    Shariat SF; Palapattu GS; Karakiewicz PI; Rogers CG; Vazina A; Bastian PJ; Schoenberg MP; Lerner SP; Sagalowsky AI; Lotan Y
    Eur Urol; 2007 Jan; 51(1):152-60. PubMed ID: 17011114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
    Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
    BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
    Sanderson KM; Cai J; Miranda G; Skinner DG; Stein JP
    J Urol; 2007 Jun; 177(6):2088-94. PubMed ID: 17509294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
    Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP
    J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy.
    Bianco FJ; Justa D; Grignon DJ; Sakr WA; Pontes JE; Wood DP
    Urol Oncol; 2004; 22(4):290-4. PubMed ID: 15283885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary invasive versus progressive invasive transitional cell bladder cancer: multicentric study of overall survival rate.
    Ferreira U; Matheus WE; Nardi Pedro R; Levi D'Ancona CA; Reis LO; Stopiglia RM; Denardi F; Rodrigues Netto N; de Cássio Zequi S; da Fonseca FP; Lopes A; Cardoso Guimarães G; de Carvalho Fernandes R; Cardenuto Perez MD
    Urol Int; 2007; 79(3):200-3. PubMed ID: 17940350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of vascular invasion in patients with bladder cancer who underwent radical cystectomy.
    Harada K; Sakai I; Hara I; Eto H; Miyake H
    Int J Urol; 2005 Mar; 12(3):250-5. PubMed ID: 15828951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
    May M; Nitzke T; Helke C; Vogler H; Hoschke B
    Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
    Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
    J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.
    Kakiashvili DM; van Rhijn BW; Trottier G; Jewett MA; Fleshner NE; Finelli A; Azuero J; Bangma CH; Vajpeyi R; Alkhateeb S; Hanna S; Kostynsky A; Kuk C; Van Der Kwast TH; Zlotta AR
    BJU Int; 2011 Feb; 107(4):540-6. PubMed ID: 21276177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy.
    Gupta A; Lotan Y; Bastian PJ; Palapattu GS; Karakiewicz PI; Raj GV; Schoenberg MP; Lerner SP; Sagalowsky AI; Shariat SF;
    Urology; 2008 Feb; 71(2):302-7. PubMed ID: 18308108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.